We recently published an article titled Excellent Earnings Propelled Prices of These 10 Firms. In this article, we are going ...

BridgeBio Pharma Inc (BBIO) reports robust financial performance and strategic advancements, driven by the successful launch ...

Analysts are intrested in these 5 stocks: ( ($CHRD) ), ( ($INMD) ), ( ($UPST) ), ( ($BBIO) ) and ( ($ATXS) ). Here is a ...

BridgeBio Pharma's robust pipeline, favorable policy shifts, and milestone payments position it for substantial future growth ...

In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against other billionaire Andreas Halvorsen’s stock picks with huge upside potential.

Shares of BBIO opened at $36.42 on Wednesday. BridgeBio Pharma has a fifty-two week low of $21.62 and a fifty-two week high of $39.47. The company’s fifty day moving average is $33.90 and its ...

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.

Analysts are estimating that BridgeBio Pharma will report an earnings per share (EPS) of $-0.86. Investors in BridgeBio ...

BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to loss of $0.05 per share a year ago. These figures ...

Below is Validea's guru fundamental report for BRIDGEBIO PHARMA INC (BBIO). Of the 22 guru strategies we follow, BBIO rates highest using our Twin Momentum Investor model based on the published ...

PALO ALTO, Calif. (AP) — PALO ALTO, Calif. (AP) — BridgeBio Pharma Inc. (BBIO) on Tuesday reported a loss of $167.4 million in its first quarter. The Palo Alto, California-based company said it had a ...